Wedbush Downgrades Compass Therapeutics to Neutral, Lowers Price Target to $1
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsDowngradesPrice Target
Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.
Wedbush analyst Robert Driscoll downgrades Compass Therapeutics (NASDAQ:CMPX) from Outperform to Neutral and lowers the price target from $5 to $1.